Thalassemia and sickle cell disease are preventable: Can two blood tests stop this cycle?

I still remember the little boy from Jharkhand who was brought to us at the age of four. Pale as paper, belly swollen with an enlarged spleen, and already showing early signs of heart strain from iron overload. He had transfusion-dependent thalassemia major. His parents — both healthy, hardworking, and completely unaware — had never been told that a simple blood test before marriage could have changed everything.

This is not a rare story. It is the daily reality for thousands of Indian families.

Every year, India sees approximately 10,000 children born with thalassemia major and another 40,000–42,000 with sickle cell disease. These are not mysterious curses. They are preventable genetic conditions. And the tools to stop them are neither expensive nor complicated.

The power of two tests

The first is pre-marital or pre-conception carrier screening — a simple blood test (CBC + HPLC) that costs less than a dinner at a decent restaurant.

It tells a young couple whether both of them carry the thalassemia or sickle cell gene. If both are carriers, there is a 25 per cent chance with every pregnancy that their child will be born with the severe disease. Armed with this knowledge, couples can make informed choices — prenatal diagnosis, IVF with genetic testing, or simply being prepared.

Countries that took this seriously have almost wiped out new births. Cyprus, once drowning in thalassemia, reduced new cases by over 90 per cent through mandatory premarital screening. Iran and parts of Italy achieved similar success. India, with 40–50 million thalassemia carriers and high sickle cell prevalence in tribal belts, has every reason to do the same.

The second test is universal newborn screening. A few drops of blood from a baby’s heel in the first few hours of life can detect sickle cell disease (SCD) as well as thalassemia major. For babies who are still born with these conditions, early diagnosis is the difference between a normal childhood and a life of crisis, disability, or early death.

A baby with SCD who receives a bone marrow transplant in the first few years of life has more than a 90 per cent chance of cure. Starting penicillin prophylaxis and hydroxyurea in infancy slashes childhood mortality dramatically. For thalassemia, early planned transplant before iron destroys the organs offers the best chance of a transfusion-free life.

The economics of inaction are brutal

A child with thalassemia major needs blood every 15–21 days for life, iron chelation, regular monitoring, and management of complications. Conservative estimates put the lifetime cost of care at ₹50 lakh to over ₹1 crore per patient, most of it borne by families or the public system through repeated hospitalisations. Multiply that by the 10,000 new thalassemia births every year, and we are looking at a future liability running into thousands of crores.

Bone marrow transplant — the established cure — costs ₹15–25 lakh if done early. Gene therapy will eventually cost more, but still far less than a lifetime of supportive care. Preventing the birth of even half of these children through carrier screening would save the country astronomical sums while sparing families unimaginable pain.

The National Sickle Cell Anaemia Elimination Mission has already screened over 6.8 crore people. That is a fantastic start. But screening without a strong continuum of care and without linking it to premarital counselling is like building a dam and leaving the gates open. We identify carriers and patients, yet we still allow new affected children to be born every single hour.

India does not need to reinvent the wheel. We need three clear, enforceable decisions:

1) Make carrier screening for thalassemia and sickle cell (CBC + HPLC) freely available and strongly promoted for every couple before marriage or first pregnancy — through district hospitals, Ayushman Bharat Health and Wellness Centres, and private labs under a government rate contract.

2) Launch a phased but time-bound universal newborn screening programme that includes hemoglobinopathies, SCID, and G6PD. Start with high-burden states and expand. The technology exists. The dried blood spot cards are cheap. The laboratories can be scaled.

3) Link positive newborn screens immediately to comprehensive care pathways — including free hydroxyurea, safe blood, and early referral for curative transplant. Public-private partnerships can accelerate this. Coal India’s Thalassemia Bal Sewa Yojana has already shown how CSR can fund transplants. The same energy can fund screening infrastructure and awareness.

A generation free of preventable suffering

I have performed hundreds of bone marrow transplants for children with thalassemia, sickle cell disease, and primary immunodeficiencies. Every successful transplant fills me with hope. But every time I see a new child wheeled in with preventable disease, I feel disheartened. We have the science. We have the tests. We even have the policy frameworks. What we lack is the final push — the political will to make prevention as important as cure.

Two simple blood tests — one before pregnancy, one at birth — can protect an entire generation. They can stop thousands of children from spending their childhoods in hospitals. They can save families from financial ruin. They can save the nation billions of rupees that can be redirected to nutrition, education, and genuine health security.

The children hooked to transfusion sets today are not asking for miracles. They are asking for a system that stops this from happening to the next child. India has eliminated polio. We can eliminate the birth of children with severe inherited blood disorders too.

The writer is a paediatric haematologist and a bone marrow transplant specialist in New Delhi.

The opinions expressed in this article are those of the author and do not purport to reflect the opinions or views of THE WEEK.